Medical Crossfire™: Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Overview:

For patients with newly diagnosed multiple myeloma (NDMM), the recommended approach has evolved from doublet to triplet combinations, and, more recently, toward quadruplet therapy. However, clinicians need clarity about which patients would benefit the most from quadruplet therapy to balance potential efficacy improvements with considerations for subsequent lines of therapy. Additionally, research is ongoing to determine how levels of measurable residual disease may help in optimizing therapy. The rapid pace and sheer volume of therapeutic developments that continue to emerge in the field of NDMM create educational and practice gaps, particularly for hematologists/oncologists who strive to deliver the best possible care to patients.

This Medical Crossfire™ program will provide both up-to-date clinical trial data and ongoing studies in NDMM, as well as an in-depth discussion with experts in MM. The Medical Crossfire® approach provides an ideal format for participants, allowing them to review patient scenarios, reflect on how they might handle particular cases, integrate relevant evidence into real-world practice, and obtain expert opinions on optimal integration of the latest therapies into treatment paradigms for patients with NDMM.

Learning Objectives:

Upon completion of this activity, participants will be able to:

• Evaluate efficacy and safety outcomes from recent clinical trials in patients with NDMM
• Individualize therapy for patients with NDMM based on recent evidence and clinical guidelines
• Implement strategies to address treatment-related adverse events in patients with NDMM
• Discuss the role of MRD assessments for guiding therapy in patients with NDMM

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.